Ratios

		vs industry	vs history
P/B	8.93	TGTX's P/B is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: 8.93 )	TGTX' s 10-Year P/B Range Min: 0.01   Max: 9.39 Current: 8.93 0.01 9.39
P/S	1666.67	TGTX's P/S is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: 1666.67 )	TGTX' s 10-Year P/S Range Min: 0.01   Max: 11.83 Current: 1666.67 0.01 11.83
EV-to-EBIT	-17.74	TGTX's EV-to-EBIT is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: -17.74 )	TGTX' s 10-Year EV-to-EBIT Range Min: 0.1   Max: 5.3 Current: -17.74 0.1 5.3

Valuation & Return

		vs industry	vs history
Price/Net Cash	14	TGTX's Price/Net Cash is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: 14 )	TGTX' s 10-Year Price/Net Cash Range Min: 4.8   Max: 4.8 Current: 14
Price/Net Current Asset Value	177.3	TGTX's Price/Net Current Asset Value is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: 177.3 )	TGTX' s 10-Year Price/Net Current Asset Value Range Min: 60.7   Max: 60.7 Current: 177.3
Price/Tangible Book	9.6	TGTX's Price/Tangible Book is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: 9.6 )	TGTX' s 10-Year Price/Tangible Book Range Min: 3.3   Max: 3.3 Current: 9.6
Price/Median PS Value	0.3	TGTX's Price/Median PS Value is ranked lower than 100% of the Companies in the Global industry. ( Industry Median: vs. TGTX: 0.3 )	TGTX' s 10-Year Price/Median PS Value Range Min: 0.1   Max: 0.1 Current: 0.3

Business Description

TG Therapeutics Inc formerly Manhattan Pharmaceuticals, Inc. was incorporated in Delaware in May 1993 under the name 'Atlantic Pharmaceuticals, Inc.' and, in March 2000, it changed its name to 'Atlantic Technology Ventures, Inc.' On February 21, 2003, the Company completed a 'reverse acquisition' of privately-held Manhattan Research Development, Inc. In connection with this transaction, it also changed its name to 'Manhattan Pharmaceuticals, Inc.' It is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. The phosphoinositide-3-kinases (PI3Ks) are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. The delta isoform of PI3K is strongly implicated in B-cell related lymphomas. Rhizen has developed novel selective inhibitors of the PI3K delta pathway, believed to be important in the proliferation and survival of B-cell lymphocytes. The lead candidate TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers.
Company Website
SEC Reports

Industry:
Compare:

» More Articles for TGTX

Headlines

Articles On GuruFocus.com

Personalized Checklist